COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS



(In thousands)	March 31, 2016			December 31, 2015
Accounts receivable, net
Accounts receivable	$	248,120		$	219,043
Less: allowance for doubtful accounts	(43,641		)	(25,168		)
	$	204,479		$	193,875
Inventories, net
Consumable supplies	$	20,759		$	22,265
Finished products	14,790			13,404
Work in-process	1,205			1,215
Raw materials	5,051			3,848
Less: inventory reserve	(1,230		)	(1,051		)
	$	40,575		$	39,681
Prepaid expenses and other current assets
Other receivables	15,122			11,946
Taxes recoverable	6,076			3,076
Prepaid supplies	10,265			8,773
Prepaid insurance	1,736			2,206
Other	306			903
	$	33,505		$	26,904
Intangible assets, net:
Customer relationships	$	451,489		$	449,972
Technologies	151,818			151,709
Trade names	50,461			50,416
Licenses	23,467			23,432
Covenants not to compete	8,619			8,612
Product registrations	7,797			7,512
Other	4,481			5,600
Less: accumulated amortization	(72,727		)	(59,101		)
	$	625,405		$	638,152
Accrued expenses:
Deferred revenue	$	74,375		$	70,246
Employee benefits	40,791			29,751
Contingent consideration	21,208			22,164
Taxes payable	5,986			7,605
Capital leases short-term	5,287			5,373
Clinical trials	5,850			2,505
Milestone payment	4,914			5,000
Professional fees	707			1,506
Other	23,224			23,749
	$	182,342		$	167,899



(In thousands)	March 31, 2016		December 31, 2015
Other long-term liabilities:
Deferred revenue	$	143,520	$	162,634
Line of credit	72,343		72,107
Contingent consideration	34,674		32,258
Mortgages and other debts payable	2,366		2,523
Capital leases long-term	8,861		9,285
Other	14,048		13,663
	$	275,812	$	292,470

All of the intangible assets and goodwill acquired relate to our acquisitions of principally OPKO Renal, OPKO Biologics, EirGen and Bio-Reference. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction we operate in.

At March 31, 2016, the changes in value of the intangible assets and goodwill are primarily due to foreign currency fluctuations between the Chilean and Mexican pesos, the Euro and the Shekel against the U.S. dollar.

The following table reflects the changes in Goodwill during the three months ended March 31, 2016.



	2016
(In thousands)	Balance at January 1st		Purchase accounting adjustments			Foreign exchange		Balance at March 31st
Pharmaceuticals
CURNA	$	4,827	$	—		$	—	$	4,827
EirGen	81,139		—			3,443		84,582
FineTech	11,698		—			—		11,698
OPKO Chile	4,517		—			195		4,712
OPKO Biologics	139,784		—			—		139,784
OPKO Health Europe	7,191		—			296		7,487
OPKO Renal	2,069		—			—		2,069

Diagnostics
Bio Reference	441,158		(321		)			440,837
OPKO Diagnostics	17,977		—			—		17,977
OPKO Lab	32,988		—			—		32,988
	$	743,348	$	(321	)	$	3,934	$	746,961